Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2003

View Archived Issues

Integrated pharmacokinetic/pharmacodynamic model developed for SB-480848

Garenoxacin pharmacokinetics similar in healthy and hepatically impaired subjects

Pharmacokinetics, metabolism and excretion of single-dose sitafloxacin in healthy males

Food intake does not alter the pharmacokinetics of multiple-dose lonafarnib

No pharmacokinetic interactions for memantine and donepezil in healthy volunteers

DOV reacquires diltiazem rights from Biovail

Results of argatroban and gpIIb/IIIa inhibitor combination study

Isis outlines 2003/4 milestones

New patent broadens protection for Virulizin

Sumitomo presents new muscarinic M3 antagonists for use in urinary incontinence

Novel PARP inhibitors in early development at Icos

JT researchers prepare and test new HIV integrase inhibitors

New antitumor duocarmycin analogues covered by Medarex patent

Novel sodium channel blockers for pain, seizures and other disorders

E.U. approval for NeoRecormon use once every two weeks for renal anemia

Metvix PDT approved in Australia

Remicade approved for long-term use in fistulizing Crohn's disease

Biosyn acquires rights to HIV microbicide candidate from NIH

AP-5346 enters phase I trials in Europe

Brand name announced for decitabine

Graffinity enters research collaboration with Serono

Ongoing program for clopidogrel in atherosclerosis

HYB-2055 enters the clinic

Water-soluble taxoids for use in tumor-activated prodrugs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...